TG Therapeutics Inc [NASDAQ: TGTX] loss -9.44% or -2.54 points to close at $24.36 with a heavy trading volume of 9594572 shares.
The daily chart for TGTX points out that the company has recorded 47.55% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 3.61M shares, TGTX reached to a volume of 9594572 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about TG Therapeutics Inc [TGTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TGTX shares is $37.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TGTX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for TG Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 29, 2024. While these analysts kept the previous recommendation, Goldman dropped their target price from $16 to $12. The new note on the price target was released on August 02, 2023, representing the official price target for TG Therapeutics Inc stock. Previously, the target price had yet another drop from $55 to $40, while Jefferies kept a Buy rating on TGTX stock.
The Average True Range (ATR) for TG Therapeutics Inc is set at 1.41, with the Price to Sales ratio for TGTX stock in the period of the last 12 months amounting to 15.29. The Price to Book ratio for the last quarter was 21.24, with the Price to Cash per share for the same quarter was set at 2.05. Price to Free Cash Flow for TGTX in the course of the last twelve months was 59.69 with Quick ratio for the last quarter at 2.83.
Trading performance analysis for TGTX stock
TG Therapeutics Inc [TGTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.04. With this latest performance, TGTX shares gained by 9.58% in over the last four-week period, additionally plugging by 47.55% over the last 6 months – not to mention a rise of 134.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 51.96, with the RSI for the last a single of trading hit 50.25, and the three-weeks RSI is set at 52.76 for TG Therapeutics Inc [TGTX]. The present Moving Average for the last 50 days of trading for this stock 23.52, while it was recorded at 25.43 for the last single week of trading, and 18.69 for the last 200 days.
TG Therapeutics Inc [TGTX]: A deeper dive into fundamental analysis
TG Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.83 and a Current Ratio set at 3.58.
TG Therapeutics Inc [TGTX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, TG Therapeutics Inc posted 0.73/share EPS, while the average EPS was predicted by analysts to be reported at 0.12/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.61. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TGTX.
An analysis of Institutional ownership at TG Therapeutics Inc [TGTX]
There are presently around $61.87%, or 68.43%% of TGTX stock, in the hands of institutional investors. The top three institutional holders of TGTX stocks are: VANGUARD GROUP INC with ownership of 13.69 million shares, which is approximately 9.3645%. BLACKROCK INC., holding 11.39 million shares of the stock with an approximate value of $$202.6 million in TGTX stocks shares; and BLACKROCK INC., currently with $$119.12 million in TGTX stock with ownership which is approximately 4.5798%.
